MK-677 vs Teriparatide
Well Studied vs Extensively Studied
synergistic Mechanism-based · 47% MK-677 and Teriparatide work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
MK-677 Teriparatide
Weight 624.77 Da 4,118 Da
Half-life ~24 hours ~1 hour (subcutaneous); ~5 minutes (intravenous)
Chain — 34 amino acids
Type Non-peptide ghrelin receptor agonist Recombinant PTH fragment
Key Benefits
MK-677
01 97% increase in 24-hour growth hormone secretion
02 40-72% elevation in IGF-1 levels
03 Enhanced sleep quality with improved REM patterns
04 Preferential lean tissue gains of 1.1-2.7kg over 8-12 months
05 15% basal metabolic rate increase within 2 weeks
06 Oral administration (no injections required)
Teriparatide
01 FDA-approved for osteoporosis treatment
02 Actively builds new bone (anabolic)
03 Increases spine bone density by 5-9%
04 Reduces vertebral fracture risk by 65%
05 Reduces nonvertebral fractures by 35%
06 Works differently than antiresorptive drugs
07 Benefits seen within 3 months
08 Creates 'anabolic window' for bone growth
Dosing Protocols
MK-677
Start 12.5mg daily, increase to 25mg based on tolerance / Once daily, preferably at bedtime on empty stomach
Teriparatide
20mcg daily (FDA-approved dose) / Once daily at same time each day
Osteoporosis treatment 20 mcg Once daily
Side Effects
MK-677
Appetite stimulation (>50% of users)
Water retention (30-40%)
Lethargy (20-30%)
Fasting glucose elevation (5-15mg/dL)
Note on testosterone suppression: at doses up to 20 mg daily, MK-677 is unlikely to cause significant testosterone suppression on its own. Above 20 mg daily, the likelihood of suppression and other side effects (insulin resistance, water retention, lethargy) increases. The case report documenting 85.7% testosterone suppression involved co-administration with LGD-4033, a SARM known to be profoundly suppressive, making the SARM the likely primary driver of that suppression.
Teriparatide
Injection site reactions
Nausea
Headache
Leg cramps
Dizziness
Joint pain
Contraindications
Heart disease or congestive heart failure
Diabetes or pre-diabetes
Active cancer
Severe cardiovascular disease
Pregnancy or breastfeeding
Paget's disease of bone
Prior skeletal radiation therapy
History of skeletal malignancies
Metabolic bone diseases other than osteoporosis
Pre-existing hypercalcemia
Pregnancy
Research Evidence
MK-677 Teriparatide
Status Well Studied Extensively Studied
References 7 studies 4 studies
Latest July 2024 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.